This treatment was demonstrated to cause inhibition function of NRF2 transcription factor and a subsequent repression of NRF2‐dependent antioxidant response pathway in ovarian cancer cells with moderate and high expression of HER2 (Khalil et al., 2016b). Here, ERBB2 is linked to ovarian carcinoma.